Independently at the University of Copenhagen, Denmark, Dr
Phase 3 data showed weight loss of 7.5% to 11.2% at 72 weeks depending on dose, with head-to-head data showing orforglipron 36 mg producing 73.6% greater weight loss than oral semaglutide 14 mg
However, the transition will likely occur gradually rather than overnight
Now that you understand how compounded GLP-1 medications and the brand-name ones differ, you might be wondering where you can find reputable compounding pharmacies that prioritize your safety
These medications are approved by the Food and Drug Administration (FDA) and are typically prescribed to patients with either a BMI greater than 30 kg/m 2 (obese) or a BMI greater than 27 kg/m 2 with a weight-related comorbidity as adjuncts to lifestyle modifications
and tirzepatide (Mounjaro, Zepbound, which works as a dual GLP-1/GIP [glucose-dependent insulinotropic polypeptide] agonist)